Recommendations for Providing Dialysis Treatment to Patients Infected with Human T-Lymphotropic Virus Type lll/Lymphadenopathy-Associated Virus

Abstract

Maintenance dialysis can be continued in patients with end-stage renal disease who have manifestations of human T-lymphotropic virus type lll/lymphadenopathyassociated virus (HTLV-III/LAV) [now known as the human immunodeficiency virus], including the acquired immunodeficiency syndrome, or who are positive for antibody to HTLV-III/LAV. These patients can be dialyzed in hospital-based or free-standing dialysis units using conventional infection-control precautions. Transmission of HTLV-III/LAV is adequately prevented by standard blood and body fluid precautions, and disinfection and sterilization procedures.